Concepedia

Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska

Michael G. Bruce, Rosalyn Singleton, Lisa Bulkow, Karen Rudolph, Tammy Zulz, Prabhu Gounder, Debby Hurlburt, Dana Bruden, Thomas Hennessy

Vaccine · 2015 · 72 citations · 25 references

DOIFull text

Open access

Abstract

Forty-five months after PCV13 introduction, overall IPD and PCV13-serotype IPD rates had decreased 58% and 83%, respectively, in Alaska children <5 years of age when compared with 2005-2008. We observed evidence of indirect effect among adults with a 39% reduction in IPD among persons 18-44 years.

References

25

Morbidity and Mortality Weekly Report

Wilderness and Environmental Medicine · 2011 · 3.4K citations

Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine

Tamara Pilishvili, Catherine Lexau, Monica M. Farley et al. · The Journal of Infectious Diseases · 2009 · 1.3K citations · Full text

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

Cynthia G. Whitney, Tamar Pilishvili, Monica M. Farley et al. · The Lancet · 2006 · 622 citations · Full text

, , +7

Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes Among Alaska Native Children With High Levels of 7-Valent Pneumococcal Conjugate Vaccine Coverage

Rosalyn Singleton, Thomas W. Hennessy, Lisa Bulkow et al. · JAMA · 2007 · 616 citations

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study

Nick Andrews, Pauline A. Waight, Polly Burbidge et al. · The Lancet Infectious Diseases · 2014 · 538 citations

, , +6